V. Bonthapally

Publications54
h-index12
Citations389
Highly Influential Citations20
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Duvic
  • 663 Publications, 22,014 Citations
  • A. Engert
  • 966 Publications, 28,923 Citations
  • N. Bartlett
  • 516 Publications, 20,461 Citations
  • P. Zinzani
  • 922 Publications, 23,191 Citations
  • Publications
  • Influence
The Direct Expenditures and Indirect Costs Associated with Treating Asthma in the United States
Historically, COI was based on one of two types of costs, total cost or incremental cost. Total costs provide estimates of the total healthcare expenditure of patients diagnosed with a disease.… Expand
  • 25
  • 4
Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
PURPOSE To review the use of patient-reported outcome (PRO) data in medical product labeling granted by the US Food and Drug Administration (FDA) for new molecular entities and biologic license… Expand
  • 31
  • 2
  • PDF
Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
AIM Metastatic breast cancer guidelines contain multiple lines of treatment and regimens; however, little data on therapeutic patterns and costs is available from real-world clinical practice. This… Expand
  • 24
  • 2
Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
Brentuximab vedotin was made available via a Named Patient Program (NPP) to non-US/Canadian patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma… Expand
  • 21
  • 2
Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.
Primary cutaneous T-cell lymphomas (CTCLs), such as mycosis fungoides and Sézary syndrome, are a rare group of non-Hodgkin lymphomas, usually treated using a multimodal approach. Unfortunately, many… Expand
  • 19
  • 2
  • PDF
Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors
Abstract Background: Patients treated with epidermal growth factor receptor inhibitors (EGFRIs) may develop dermatologic adverse drug reactions (ADRs) that may affect patients’ quality-of-life,… Expand
  • 11
  • 2
Costs, length of stay, and mortality of super‐refractory status epilepticus: A population‐based study from Germany
Super‐refractory status epilepticus (SRSE) is a severe condition in which a patient in status epilepticus (SE) for ≥24 h does not respond to first‐, second‐, or third‐line therapy. The economic… Expand
  • 75
  • 1
Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
Peripheral T-cell lymphomas (PTCLs) tend to be aggressive and chemorefractory, with about 70% of patients developing relapsed/refractory disease. Prior to 2009, chemotherapies were the only options… Expand
  • 28
  • 1
Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer
Brain metastases are a frequent complication of many systemic cancers and portend a poor prognosis. This retrospective analysis of health claims data compared survival, treatment and health care… Expand
  • 21
  • 1
Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey.
BACKGROUND The differences in country-specific treatment patterns across Europe for metastatic breast cancer (mBC) patients have not been extensively studied. This study compared the treatment… Expand
  • 16
  • 1